PCP
ITCI

Proficio Capital Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Proficio Capital Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-29
Closed – – 2111
2019
Q1 		$0 Buy
+29
New +$371 ﹤0.01% 1790

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Proficio Capital Partners's ITCI Position: Q2 2019 in Review

Proficio Capital Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2019, closing a stake of 29 shares.

Proficio Capital Partners first reported a position in ITCI in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 126 funds tracked by Wall St. Rank hold ITCI as of Q2 2019.

  • Proficio Capital Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 29 Intra-Cellular Therapies Inc. shares in Q2 2019.
  • Proficio Capital Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2019 and held it in 1 quarter.
  • Proficio Capital Partners's Intra-Cellular Therapies Inc. position peaked at $0 in Q1 2019.
  • 126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2019.

Based on Proficio Capital Partners's 13F filing for Q2 2019, filed 13 Aug 2019.